Sequencing BCMA Myeloma Therapies
Let's learn together what we know about sequencing BCMA therapies, and what there's left to learn. As more immunotherapies targeting BCMA on cancerous myeloma plasma cells continue to be develop, there is question about which combination of these treatments is most efficacious, and what precautions need to be taken when using such similar targeted therapies. Join Dr. Josh Richter, a myeloma specialist, as he shares information regarding this topic.
Audrey introduces the agenda of the event and featured speaker Dr. Joshua Richter.
Dr. Joshua Richter shares about sequencing BCMA therapies.
Type your questions in the chat and we will answer them!
Audrey Burton-Bethke
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Joshua Richter, MD
Joshua Richter, MD, is Associate Professor of Medicine in The Tisch Cancer Institute, Division of Hematology and Medical Oncology. He is the director of Multiple Myeloma at the Blavatnik Family- Chelsea Medical Center at Mount Sinai. Dr. Richter treats patients with plasma cell dyscrasias, including multiple myeloma and related diseases such as AL amyloidosis, plasma cell leukemia, and Waldenstrom’s Macroglobulinemia. Dr. Richter has extensive experience with clinical trials focused on novel therapies, including antibody therapy and immunotherapy for a precision medicine approach. He has published extensively on these topics and has been invited to speak regionally, nationally, and also internationally. He has been published in journals such as the New England Journal of Medicine, Blood, and the Journal of Clinical Oncology.